Therapeutic Drug Monitoring

Antieleptics

Gabapentin

Lacosamide

Lamotrigine

Levetiracetam

Oxcarbazepine Metabolite

Topiramate

Zonisamide

Anti-Cancer

Methotrexate

Methotrexate II

Antibiotics

Linezolid

Antifungals

Voriconazole

ARK Methotrexate II Assay

ARK Diagnostics Inc. has further enhanced its trusted ARK™ Methotrexate Assay to provide even greater accuracy, reliability and efficiency for your diagnostics. The new ARK Methotrexate II Assay utilizes a monoclonal antibody to ensure consistently high lot-to-lot quality – so you can rely on results of the highest precision and reproducibility.
With an improved calibration curve resolution, superior precision – especially at low concentration ranges – and significantly reduced cross-reactivity with the primary metabolite 7-hydroxymethotrexate (≤ 0.01%), the ARK Methotrexate II Assay supports more effective patient management and helps reduce hospitalization times.
Assay Highlights
  • Monoclonal antibody ensures consistent lot quality
  • Exceptional sensitivity, precision, linearity, and stability
  • Minimal cross-reactivity with 7-hydroxymethotrexate (≤ 0.01%)
  • Improved limit of detection (LOD) and limit of quantification (LOQ)
  • Applications for all major clinical chemistry analyzers
  • Liquid, ready-to-use reagents, calibrators, and controls

Clinical Background

Methotrexate is an antimetabolite commonly used in adults to treat a variety of neoplastic diseases. Due to its potential for serious side effects, close monitoring of methotrexate levels is essential to detect toxicity early and optimize therapy.

Therapeutic drug monitoring is particularly important during high-dose methotrexate treatments. Accurate and timely measurements help clinicians adjust supportive care effectively. Clinical guidelines recommend leucovorin (citrovorum factor) rescue therapy in conjunction with moderate to high doses of methotrexate (approximately 35 mg/m² to 12 g/m²). This treatment approach has shown efficacy in managing osteogenic sarcomas, leukemia, non-Hodgkin lymphomas, and certain solid tumors such as lung and breast cancers.

PDF

Do you have any questions for us?